What is IRON's current stock price?

IRON (Disc Medicine, Inc.) is currently trading at $66.82 with a market cap of $2.55B.

What sector is Disc Medicine, Inc. in?

Disc Medicine, Inc. (IRON) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IRON a good stock to buy?

Analysts have a Buy consensus on IRON with a price target of $103.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IRON Disc Medicine, Inc.

Healthcare

$66.82-0.46%ClosedMarket Cap: $2.55B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.74

P/S

0.00

EV/EBITDA

-10.21

DCF Value

$2.31

FCF Yield

-7.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-36.9%

ROA

-32.2%

ROIC

-36.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-63.5M	$—
Q4 null	$0.00	$-60.5M	$—
FY null	$0.00	$-212.2M	$—
Q3 null	$0.00	$-62.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$103.33

Target (Median)

$105.00

Target Range

$80.00 - $125.00

1 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Morgan StanleyOverweight

2026-05-14

Wells FargoOverweight

2026-03-02

Truist SecuritiesBuy

2026-02-27

StifelBuy

2026-02-17

BMO CapitalOutperform

2026-02-17

Trading Activity

Insider Trades

View All

Savage William Jacobofficer: Chief Medical Officer

SellWed Apr 15

Savage William Jacobofficer: Chief Medical Officer

SellWed Apr 15

Franchi Jean M.officer: Chief Financial Officer

SellWed Apr 15

Franchi Jean M.officer: Chief Financial Officer

SellWed Apr 15

Savage William Jacobofficer: Chief Medical Officer

SellWed Mar 04

Latest News

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPRNewsWire · Mon May 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.14

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Peers